# A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects

> **NCT00443170** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 90 (actual)

## Conditions studied

- Healthy Subjects
- Anaemia

## Interventions

- **DRUG:** GSK626616, placebo, midazolam
- **DRUG:** omeprazole, caffeine, flurbiprofen, rosiglitazone

## Key facts

- **NCT ID:** NCT00443170
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2012-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00443170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00443170, "A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00443170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*